![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Week 96 Resistance Surveillance for HBeAg Positive and Negative Subjects with Chronic HBV Infection Randomized to Receive Tenofovir DF 300 mg QD
|
|
|
Reported by Jules Levin
13th ISVHLD Wash Dc March 20-24 2009
A Snow-Lampart1, B Chappell1, M Curtis1, Y Zhu1, J Heathcote2,
P Marcellin3, K Borroto-Esoda1
1Gilead Sciences Inc., Durham, NC, USA; 2University of Toronto, Toronto ON, Canada; 3University of Paris, Hospital Beaujon, Clichy, France
![conclusion-1.gif](../images/032709/conclusion-1.gif)
![objection-2.gif](../images/032709/objection-2.gif)
![method-3.gif](../images/032709/method-3.gif)
![plan-4.gif](../images/032709/plan-4.gif)
![Median-5.gif](../images/032709/Median-5.gif)
![TDF-6.gif](../images/032709/TDF-6.gif)
![WT-7.gif](../images/032709/WT-7.gif)
![Viro-8.gif](../images/032709/Viro-8.gif)
![Sites-9.gif](../images/032709/Sites-9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|